Phase 1/1b Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors (MYTHIC Study)

Contact:

NCT Number:

Protocol:

AAAT6971

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I

The purpose of this research study is to test how safe RP-6306 is at different doses and schedules, test how well RP-6306 works to shrink cancer in the body, and evaluate if food affects the way RP-6306 moves through your body. This study will test the investigational drug, RP-6306, for the first time in humans. “Investigational” means that the study drug being tested has not been approved by the United States Food and Drug Administration (FDA). RP- 6306 is a PKMYT1 inhibitor (blocks the activity of the PKMYT1 protein) that is designed to stop certain cancer cells from growing. You are being asked to participate in this study because you have an advanced cancer with a specific genetic change that is predicted to be sensitive to the study drug.

Are you Eligible? (Inclusion Criteria)

  • You have an advanced cancer with a specific genetic change that is predicted to be sensitive to the study drug
  • You are at least 18 years-of-age
  • Archived tumor tissue available

Specialty Area(s)

Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Gynecologic Cancers, Ovarian Cancer, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer

Principal Investigator

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032